AstraZeneca and 武田 establish collaboration to develop and commercialise MEDI1341 for Parkinson’s disease

AstraZeneca and 武田 Pharmaceutical Company Limited today announced that they have entered an agreement to jointly develop and commercialise MEDI1341, an alpha-synuclein antibody currently in development as a potential treatment for Parkinson’s disease (PD).

α-突触核蛋白(α-核蛋白) is an aggregation-prone protein that contributes to the development of PD. This protein is the major constituent of Lewy bodies, which are pathological protein aggregates that accumulate in the nerve cells of patients with PD and appear to spread throughout the nervous system during the progression of the disease. These insights support the development of new PD medicines that seek to remove existing pathological alpha-synuclein aggregates, 防止它们形成, 或者阻止它们扩散. Such therapies could potentially prevent or delay the onset of PD, or halt or slow its progression.

MEDI1341 is an antibody that is differentiated by its high affinity, high selectivity and reduced effector function (lower interaction with the immune system), which has the potential to achieve a better efficacy and safety profile than other alpha-synuclein antibodies. MEDI1341 is due to enter Phase I clinical trials later this year.

Mene Pangalos, Executive Vice President, Innovative 药物 & Early Development Biotech Unit and Global Business Development at AstraZeneca, said: “Today there are no medicines that can slow or halt the degenerative progress of Parkinson's disease so this remains a large area of unmet medical need. 武田 has an excellent track record in neuroscience research and we are excited to be working together. By combining our scientific expertise and sharing the risks and cost of development, we hope to accelerate the advancement of MEDI1341 as a promising new approach to support the treatment of people with Parkinson’s disease around the world.”

Emiliangelo Ratti, Head, 全球中枢神经系统治疗区域单位, 武田, said: “Despite modest advancements in maintenance therapies, Parkinson’s disease continues to represent a devastating diagnosis and a burdensome challenge for therapeutic discovery. Our collaboration with AstraZeneca is a sophisticated one that will enable us to efficiently advance a validated target in a new modality, with the aim of improving the lives of patients.”

Contractual and financial considerations

根据协议条款, AstraZeneca will lead Phase I development while 武田 will lead future clinical development activities. The companies will share equally future development and commercialisation costs for MEDI1341, 以及未来的收入. 武田 will pay AstraZeneca up to $400 million, including initial revenue in 2017 and development and sales milestones thereafter. Additional terms of the agreement are not disclosed.

给编辑的说明

关于帕金森病

Parkinson's disease is the second most common neurodegenerative disease, after Alzheimer’s disease.¹ An estimated seven to ten million people worldwide are living with Parkinson’s disease. The combined direct and indirect cost of Parkinson’s, 包括治疗, social security payments and lost income from inability to work, is estimated to be nearly $25 billion per year in the United States alone.²

关于澳门在线赌城娱乐

澳门在线赌城娱乐是一家全球性的, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - 肿瘤学, 心血管 & 代谢性疾病和呼吸系统疾病. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

欲了解更多信息，请访问 www.澳门在线赌城娱乐.com 并在推特上关注澳门第一赌城在线娱乐@AstraZeneca.

参考文献

1. http://www.niehs.nih.gov/research/supported/health/neurodegenerative/index.cfm

2. http://www.pdf.org/parkinson_statistics

联系人